If you’re suffering from psoriasis or psoriatic arthritis (PsA), we’re here to help. We are fully committed to managing these conditions and to developing effective treatments to reduce joint inflammation and pain. We understand the pain that comes with immune-mediated diseases, and are working to relieve the stress that they can cause to patients and their loved ones.
Our focus in Rheumatology: psoriatic arthritis (PsA)
For more than two decades, Janssen has been providing patients and physicians with important therapies to treat psoriatic arthritis (PsA), rheumatoid arthritis (RA) and other rheumatic diseases.
Psoriatic arthritis (PsA) is a chronic immune-mediated condition that is characterised by joint inflammation, most commonly of the hands and feet. Other parts of the body may also be affected, such as the tendons and ligaments.
Rheumatoid Arthritis (joint inflammation)
What we’ve achieved
Janssen is at the forefront of new treatment development in rheumatic diseases, beginning with the development of tumour necrosis factor- (TNF) alpha inhibitors, as well as other biological treatments.
We’re committed to developing better treatments for those living with psoriatic arthritis, given the physical and psychological effect it has on people living with the condition.
In future, we aim to provide effective therapeutic options for everyone, from people with early and mild stages of immune-mediated disease, all the way to those with severe forms of the disease and those who have run out of treatment options.
Our aim is to restore balance to the immune system with innovative treatments that either engage the brakes or block the accelerators of the immune system. Our goal is to use these therapeutic approaches simultaneously to provide patients with even better outcomes.
We will not rest until we achieve a world where immune-mediated inflammatory disease is a thing of the past.
Psoriatic arthritis facts
Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease that causes inflammation (including swelling) of the joints and often red, raised skin plaques called psoriasis. PsA may affect both the joints and connective tissue (entheses), causing pain, stiffness and swelling.
Symptoms of PsA commonly appear between the ages of 30 and 50, but can develop at any time, affecting both men and women equally.
It’s important to start treatment as quickly as possible with PsA because over time, the associated inflammation can cause worsening joint damage. If this becomes severe, there is a risk of permanent joint problems or deformity, making everyday tasks difficult.
The impact of the disease can extend beyond joint and skin symptoms:
More than half of people with PsA have at least one additional medical condition (known as a ‘comorbidity’). Up to 40% of people with PsA have three or more comorbidities.
People with PsA can also develop cardiovascular disease, and metabolic comorbidities such as obesity or diabetes. These conditions can lead to reduced quality of life, high healthcare costs, and more complex PsA treatment., 
Beyond Expectations patient platform
If you want to learn more about psoriasis or psoriatic arthritis, check out Beyond Expectations. It’s an online patient portal for those who live with psoriatic disease or are interested in learning more about the disease and treatment options. It’s also a place to connect with others via patient groups.
The platform provides tips, patient stories, and credible, scientifically supported information to help and encourage people to move forward with their lives. As well as finding inspiration on how to live their lives, we want patients to see that any progress is something to be proud of, and that their condition does not define them.
We believe that with the right tools there are no limits to what patients can achieve. Every day can – and should – be filled with triumphs, big and small.
 Lenman M and Sonya A. Diagnosis and management of psoriatic arthropathy in primary care. British Journal of General Practise. 2014; 64(625); 424-425.
 Busse K and Liao W. Which Psoriasis Patients Develop Psoriatic Arthritis? Psoriasis Forum. 2010;16(4):17–25.
 Coates LC and Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17(1):65–70.
 American College of Rheumatology. Psoriatic Arthritis. Available at: https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Condition.... Accessed October 2022.
 Belasco J and Wei N. Psoriatic Arthritis: What is Happening at the Joint? Rheumatol Ther. 2019;6(3):305–315.
 Coates, L.C. et al. Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity. BMC Rheumatol. 2018 2;24.
 Betteridge N, et al. Promoting patient-centred care in psoriatic arthritis: A multidisciplinary European perspective on improving the patient experience. J Eur Acad Dermatol Venereol. 2016;30(4):576–85.
 Kotsis K, et al. Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health-related quality of life. Arthritis Care. 2012. Res (Hoboken). 2012;64(10):1593–601.
 Gossec L, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73(6):1012–1019.
 Arthritis Foundation. Metabolic Comorbidities of Psoriatic Arthritis. Available at: https://www.arthritis.org/health-wellness/about-arthritis/related-condit... . Accessed October 2022.
 Lee S, et al. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P.T. 2010;35(12):680-689.